Estimation of quality of life in patients, suffering cardiomyopathy of ischemic genesis, depending on the method of treatment
Objective. To estimate the changes of the patients’ quality of life in those, suffering ischemic cardiomyopathy after surgical revascularization and transplantation of the stem cells, obtained from umbilical blood.
Materials and methods. There was analysis conducted on changes in quality of life in 113 patients, suffering cardiomyopathy of ischemic genesis. In accordance to the therapeutic method applied, the patients were divided into four groups: first - 38 (33.6%) patients, in whom coronary shunting was conducted, the second - 35 (31.0%) patients, in whom coronary arteries stenting was done, the third - 20 (17.7%) patients, in whom surgical revascularization was added by transplantation of the umbilical blood stem cells; and the fourth - 20 (17.7%) patients, in whom conservative therapy only was administered.
Results. Estimation of efficacy of the stem cells, obtained from umbilical blood, was conducted, in accordance to the points quantity reduction, using the data from The Minnesota Living with Heart Failure Questionnaire (MLHFQ), by 50.0% in 12 mo of observation. This enhancement of therapeutic efficacy in aspect of the quality of life improvement after complex application of the myocardium revascularization and transplantation of the umbilical blood stem cells have constituted 75.0%, comparing with conservative therapy, 53.7% - comparing with coronary shunting and 48.6% -comparing with the coronary arteries stenting. There was proved the essential raising of probability for achievement of this effect, as well as a probable cumulative restoration of the chances - 4.85 [2.44 - 964]. In accordance to the SF-36 questionnaire answers data; trustworthily higher indices for the physical and psychological health components were obtained in patients, in whom myocardial revascularization were added by the umbilical blood stem cells.
Conclusion. After transplantation of stem cells, obtained from umbilical blood, as the additive to the myocardial revascularization for treatment of ischemic cardiomyopathy, the signs of cardiac insufficiency have diminished, tolerance for any physical loading partly renewed, including solemn round of industry and a self-servicing, as well as the indices for the physical and psychological health improved.
Alba AC, Foroutan F, Duero Posada J, Battioni L, Schofield T, Alhussein M, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018;104(3): 230-6. PMID: 28780582. doi: 10.1136/heartjnl-2017-311430.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur. Heart Jour. 2016;37:2129-2200. PMID: 27206819. doi: 10.1093/eurheartj/ehw128.
Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clin Med Insights Cardiol. 2018;12: 1179546817751609. PMID: 29343997. doi: 10.1177/1179546817751609.
Papa AA, D'Ambrosio P, Petillo R, Palladino A, Politano L. Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series. Intractable Rare Dis Res. 2017;6(2):95-101. PMID: 28580208. doi: 10.5582/irdr.2017.01024.
Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report - 2013; Focus Theme: Age. J Heart Lung Transplant. 2013;32(10): 951-64. PMID: 24054804. doi: 10.1016/j.healun.2013.08.006.
Liao SY, Tse HF. Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons? Stem Cell Res Ther. 2013;4(6):151. PMID: 24476362. doi: 10.1186/scrt381.
Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810-34. PMID: 23989721. doi: 10.1161/CIRCRESAHA.113.300219.
Mathur A, Arnold R, Assmus B, Bartunek J, Belmans A, Bönig H, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. Eur J Heart Fail.2017;19(11):1545-50. PMID: 28948706. doi: 10.1002/ejhf.829.
Zholdasbekova AS, Kalmatayeva ZhA. Sovremennye podhody k izucheniju kachestva zhizni v medicine i kardiologii (literaturnyj obzor). Vestnik KazNMU. 2016;(3):246-51. [In Rbssian].
Garin O, Ferrer M, Pont I, Wiklund I, Van Ganse E, Vilagut G, et al. Evidence on the global measurement model of the Minnesota Living with Heart Failure Questionnaire. Qual Life Res. 2013;22(10):2675- 84. PMID: 23677481. doi: 10.1007/s11136-013-0383-z.
Pelle AJ, Kupper N, Mols F, de Jonge P. What is the use? Application of the short form (SF) questionnaires for the evaluation of treatment effects. Qual Life Res. 2013 Aug;22(6):1225-30. PMID: 22975926. doi: 10.1007/s11136-012-0266-8.
This work is licensed under a Creative Commons Attribution 4.0 International License.